Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018

Satimai Aniwan; Julajak Limsrivilai; Supot Pongprasobchai; Nonthalee Pausawasdi; Piyapan Prueksapanich; Natanong Kongtub; Rungsun Rerknimitr

doi:10.5217/ir.2020.00028

Articles

Page Path: HOME > Intest Res > Volume 19(2); 2021 > Article

Original Article Inflammatory Bowel Diseases Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018: Satimai Aniwan^1,2,, Julajak Limsrivilai³, Supot Pongprasobchai³, Nonthalee Pausawasdi³, Piyapan Prueksapanich^1,2, Natanong Kongtub^1,2, Rungsun Rerknimitr^1,2; Intestinal Research 2021;19(2):186-193.
DOI: https://doi.org/10.5217/ir.2020.00028
Published online: August 18, 2020

¹Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

²King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand

³Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand

Correspondence to Satimai Aniwan, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road Pattumwan, Bangkok 10330, Thailand. Tel: +66-2-256-4265, Fax: +66-2-252-7839, E-mail: satimai@gmail.com

• Received: February 17, 2020 • Revised: April 25, 2020 • Accepted: May 23, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

6,801 Views
187 Download
13 Web of Science
13 Crossref
13 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
The incidence of ulcerative colitis (UC) in Thailand (crude incidence rate of 0.28 per 100,000 persons) is much lower than in the West. The burden of UC varies in different populations. The aim of this study was to evaluate the natural history of UC over the two decades in Bangkok, Thailand.
Methods
This retrospective study included patients who were diagnosed with UC between 2000 and 2018 in 2 university hospitals. To evaluate changes in the disease course, we stratified patients into 2000–2009 cohort and 2010–2018 cohort. The cumulative probability of endoscopic healing, UC-related hospitalization and colectomy was estimated using the Kaplan-Meier method.
Results
A total of 291 UC patients were followed for total of 2,228 person-years. Comparison between 2 cohorts, there were no differences in disease pattern and severity whereas an increase in the combination use of oral and topical mesalamine and the early use of thiopurine was observed. Only 1% of patients for each cohort required biologic agent at 5 years. The rate of achieving mucosal healing increased from 15% to 46% at 3 years (P<0.01). The rate of UC-related hospitalization decreased from 30% to 21% at 5 years (P<0.05). The rate of colectomy decreased from 6% to 2% at 5 years (P<0.05).
Conclusions
The natural history of UC in a low incidence country was less aggressive than the West. Over the past two decades, the rates of UC-related hospitalization and colectomy have been decreasing which were similar to the West.
Keywords: Colitis, ulcerative; Inflammatory bowel disease; Epidemiology; Natural history

INTRODUCTION

Ulcerative colitis (UC) is an incurable chronic disease that commonly develops at young ages and lasts throughout life, impacting quality of life. Although a recent systematic review showed that more than 80% of studies from high prevalence regions such as North America and Western Europe reported a plateau or decreased incidence of UC, the prevalence of UC remains high. In contrast, a low prevalence region, such as Asia, which has newly industrialized countries, is facing increasing incidence [1]. Therefore, changing the epidemiology of UC in the next decade will challenge health care systems worldwide.

The burden of UC varies in different countries and populations. Although UC is not associated with an increased risk of mortality [2], it is associated with high morbidity [3]. Because of the complex and incurable nature of the disease, understanding the natural history of UC is important to prepare health care resources and policies for this chronic and costly disease. A systematic review of the natural history of UC that included several studies from high incidence countries reported that approximately 50% of patients with UC required corticosteroids at 10 years, the rate of UC-related hospitalization at 10 years was 50%, and the rate of colectomy at 10 years was 10% to 15% [3]. However, long-term studies from low incidence countries are lacking. In Asia-Pacific region, Thailand had the lowest incidence of UC (crude incidence of 0.28 per 100,000 persons) [4].

Hence, we aimed to evaluate the natural history of adult UC in a low incidence area and changes of disease course regarding the rates of endoscopic healing, hospitalization and colectomy between 2000 and 2018.

METHODS

1. Study Setting and Study Population

We conducted a retrospective study in 2 university hospitals (Siriraj Hospital and King Chulalongkorn Memorial Hospital) from Bangkok, Thailand. All patients were required to meet the diagnosis criteria of UC on the basis of clinical symptoms, diffusely granular or friable colonic mucosa, and continuous mucosal involvement based on endoscopy and histology [2,5]. We excluded UC patients who were diagnosed from outside our institutes. Cases were included only for the remaining UC diagnosis at 6 months after the first date of diagnosis. Infections, intestinal tuberculosis, amoebiasis, and drug-induced colitis were excluded. The index date was based on the first UC diagnosis. The medical records of patients with UC were retrospectively reviewed from the date of first UC diagnosis until the end of the study (December 31, 2018) by 2 experts (S.A. and J.L.). The study protocol was approved by the ethics committees of each institute (Chulalongkorn IRB No. 398/53 and Siriraj IRB No. 710/2561). The informed consent was waived.

2. Treatment Strategy

In our practice, the treatment strategy is based on a step-up approach. For mild to moderate disease activity, mesalamine (topical and/or oral) is prescribed as induction and maintenance. For severe disease activity, systemic corticosteroids are prescribed. Thiopurine is prescribed for steroid-dependent UC. Biologic agents are prescribed for steroid refractory or steroid dependent with thiopurine nonresponsive/intolerant. During the study period, infliximab and vedolizumab are available for UC indication in Thailand. According to the Food and Drug Administration of Thailand, infliximab has been approved since 2003 and vedolizumab has been approved since 2017. Infliximab was able to be reimbursed since 2009. The criteria for reimbursement of infliximab are steroid refractory or steroid dependent with thiopurine nonresponsive/intolerant. Nowadays, vedolizumab is non-reimbursable. Colectomy is considered for severe UC refractory to medical treatment. Colectomy in UC patients is only performed at our institutes. Patients with induction therapy are followed up every 1–2 months and patients with maintenance therapy are followed up every 3–6 months at the inflammatory bowel disease clinic in our institutes. Endoscopic assessment is performed within a 6- to 12-month interval after treatment initiation.

3. Data Collection

At UC diagnosis, data on demographic characteristics, smoking status, symptom duration before diagnosis, and disease extent were collected. During the follow-up period, data on endoscopic healing, UC-related hospitalization and colectomy were collected. Data regarding UC treatment was collected as follows: (1) ever used oral mesalamine; (2) ever used combined topical and oral mesalamine; (3) ever used systemic corticosteroid; (4) ever used thiopurine and date of initiation; (5) ever used biologic agent and date of initiation; (6) at least one hospital admission more than 24 hours and date of first admission; and (7) colectomy and date of first colonic resection. We defined requiring systemic corticosteroid, biologic agent, and colectomy due to medical failure as markers of disease severity. The extent of disease was defined according to the Montreal classification as proctitis (E1), left-sided colitis (E2) and extensive colitis (E3). We defined mucosal healing as Mayo endoscopic subscores (0-1).

4. Statistical Analysis

The chi-square or Fisher exact test was used for 2 proportions of data comparison. Independent t-tests or the Mann-Whitney U test was used for 2 continuous data comparison. To assess changes in the disease course of UC, we stratified patients into 2 cohorts: (1) 2000–2009 cohort–patients with UC diagnosis during the calendar year of 2000–2009 and (2) 2010–2018 cohort–patients with UC diagnosis during the calendar year of 2010–2018. The cumulative probability of endoscopic healing, UC-related hospitalization and colectomy was estimated using the Kaplan-Meier method. The log-rank test was used to compare the disease course of UC between the 2 cohorts. Cox proportional hazards analyses were used to assess association between baseline factors (sex, age < 40 years at diagnosis, body mass index, smoker, extensive colitis, extraintestinal manifestation and calendar period of UC diagnosis) and time from UC diagnosis to first event of achieving endoscopic healing, UC-related hospitalization, and colectomy expressed in hazard ratio (HR) with 95% confidence interval (CI). We included variables with a P<0.1 in the univariate analysis in the multivariate analysis model. We considered statistically significant as an alpha level of 0.05. Statistical analyses were performed by using SPSS Statistics version 23.0 (IBM Corp., Armonk, NY, USA).

RESULTS

1. Patient Characteristics

A total of 291 patients with UC (119 patients diagnosed in 2000–2009 and 172 patients diagnosed in 2010–2018) were followed for total of 2,228 person-years. The median follow-up duration in 2000–2009 cohort was 10 years (interquartile range [IQR], 7–13 years) and 4 years (IQR, 2–7 years) in 2010–2018 cohort. The median age at UC diagnosis was 42 years (IQR, 32–55 years), and 53% of patients were female. There were nonsmokers (n = 261, 90%), former smokers (n = 27, 9%) and active smokers (n = 3, 1%). Twelve patients (4%) underwent appendectomy. None of the patients had a family history of inflammatory bowel disease. At diagnosis, the disease extent was distributed as E1 (n = 62, 21%), E2 (n = 103, 35%), and E3 (n = 126, 43%). During study period, 23 (14%) patients with either E1or E2 at diagnosis had disease progression to E3. Eighty-one (68%) patients in the 2000–2009 cohort and 112 (65%) patients in the 2010–2018 cohort experienced severe disease (P=0.60). There was no difference in patient characteristics between 2 cohorts (Table 1).

2. Medications

Comparing between the 2 cohorts, the use of combination treatment of oral and topical mesalamine in the 2010–2018 cohort (49%) significantly increased when compared with the use in the 2000–2009 cohort (29%, P<0.05). For systemic corticosteroids, there was no difference in any use of corticosteroids between the 2 cohorts (63% vs. 64%, P=0.87). For thiopurine use, a significant increase in the use of thiopurine between the 2 cohorts was observed. The median duration from diagnosis to thiopurine initiation in the 2000–2009 cohort was 24 months and 11 months in the 2010–2018 cohort (P<0.01). The cumulative probability of receiving thiopurine was 21% versus 29% at 1 year and 35% versus 49% at 3 years and 42% versus 63% at 5 years after diagnosis between the 2000–2009 cohort and the 2010–2018 cohort (P=0.01) (Fig. 1A). Only 3 patients in the 2000–2009 cohort and 1 patient in the 2010–2018 cohort required biologic agents. The cumulative probability of receiving biologic agents was 1% at 5 years after diagnosis for both cohorts.

3. Endoscopic Healing

A total of 252 patients with UC underwent endoscopic evaluation after treatment. There was a significant increase in the mucosal healing rate between the 2 cohorts. The cumulative probability of achieving mucosal healing was 8% versus 16% at 1 year, 15% versus 46% at 3 years and 27% versus 58% at 5 years after diagnosis between the 2000–2009 cohort and the 2010–2018 cohort (P<0.01) (Fig. 1B). Table 2 shows the Cox proportional hazards analysis models for the association of baseline factors and the risk of achieving endoscopic healing. In multivariate analysis, a decreased risk of achieving endoscopic healing was observed in patients with age < 40 years at diagnosis (adjusted HR [aHR], 0.69; 95% CI, 0.48–1.00) and those with UC diagnosis in 2000–2009 (aHR, 0.54; 95% CI, 0.37–0.79).

4. Hospitalization

Among 291 patients with UC, 62 patients (21%) required at least one hospitalization at some point during the disease course (33 patients from the 2000–2009 cohort and 29 patients from the 2010–2018 cohort). There was a significant decrease in the rate of UC-related hospitalization in the 2010–2018 cohort when compared with those in the 2000–2009 cohort (P<0.05). The cumulative probability of requiring UC-related hospitalization was 18% versus 5% at 1 year, 28% versus 12% at 3 years, and 30% versus 21% at 5 years in the 2000–2009 and 2010–2018 cohorts (P=0.048) (Fig. 2A). Table 3 shows the Cox proportional hazards analysis models for the association of baseline factors and the requirement of UC-related hospitalization. In multivariate analysis, patients with extensive colitis (aHR, 2.82; 95% CI, 1.66–4.82) and those with UC diagnosis in 2000–2009 (aHR, 1.70; 95% CI, 1.03–2.81) were significantly associated with developing UC-related hospitalization.

5. Colectomy

Sixteen of 291 patients with UC underwent colectomy at maximal follow-up of the study (11 from the 2000–2009 cohort due to medical failure [n = 8], superimposed severe cytomegalovirus colitis [n = 2], high-grade dysplasia of colon [n = 1] and 5 from the 2010–2018 cohort due to medical failure [n = 5]). The rate of colectomy in the 2010–2018 cohort significantly decreased when compared with the 2000–2009 cohort (P<0.05). The cumulative probability for colectomy at 5 years after diagnosis was 6% in the 2000–2009 cohort and 2% in the 2010–2018 cohort (P=0.04) (Fig. 2B). In multivariate analysis, although not statistically significant, the risk of colectomy was also found in patients with extensive colitis (aHR, 1.96; 95% CI, 0.69–5.51) and those with UC diagnosis in 2000–2009 (aHR, 2.81; 95% CI, 0.92–8.61) (Table 3).

6. Colorectal Cancer and UC-Related Death

None of patients had colorectal cancer. One patient maintaining with thiopurine in the 2000–2009 cohort deceased from severe bacterial pneumonia. No death occurred in the 2010–2018 cohort.

DISCUSSION

In the present study, we observed that the patient’s characteristics and the disease extension at diagnosis of UC remained stable over time. There was a less aggressive disease course of UC. Approximately, 60% of patients had E1/E2 and about 14% of those patients developed E3 on follow-up. Although twothirds of patients experienced active disease that required systemic corticosteroid during their disease course, approximately the overall 5-year cumulative risk of requiring hospitalization was 25% and the overall 5-year cumulative risk of colectomy was 5%. These rates have been declined over time that corresponds with an increase in the use of thiopurine (63%), but not biologic use (1%).

There was no sex difference in our study population. Our findings are in line with a pooled analysis of incidence from Western studies [6]. The disease locations of UC in our study were generally similar to those in the Western [3,7], Australian [4], and Asian populations [4]. However, the overall rate of progression to extensive colitis was 14%, which was comparable to the Asia population (12%) [8] but less than that in the Copenhagen study (28%) [9]. In addition, the overall rate of requiring corticosteroid use in our study was approximately 63%, which was relatively less than that in the Sweden study (71%) [7].

The paradigm shifts in UC management such as early initiation of thiopurine and treatment target for endoscopic remission during the two decades were observed. We found a significantly increased proportion of patients with UC diagnosed in the 2010s who received more combinations of oral and topical mesalamine. The shorter time to initiate thiopurine after diagnosis and the proportion of thiopurine users has significantly increased during two decades. In the 2000s, approximately 20% of patients with UC used thiopurine in the first year after diagnosis and increased to 30% of patients with UC in the 2010s. This is in accordance with Dutch study, where there was a 2- to 3-fold increased thiopurine user from 8% in 1991–1997 to 23% in 1998–2006 [10]. For biologic agents, we did not find the changes in the use of biologic agent in our population. The overall biologic agent use was only 1% for both the 2000s and 2010s in our population. In contrast, an increase in the first year use of biologic agent (5%–10%) was found more in the West population [9-11]. A Canadian cohort in 2014 reported that the cumulative incidence of biologic agent use within 5 years of diagnosis was 7.8% [12]. This may explain by the disease course in our population, which was less severity, and then was able to control inflammation with conventional treatment. Regarding endoscopic remission, we demonstrated the significantly increased proportions of mucosal healing during two decades. The cumulative probability for achieving endoscopic healing within 3 years of the disease course was 15% in the 2000s and increased to 46% in the 2010s.

We found that the evolution of UC management, including the use of a combination of oral and topical mesalamine [13], early use of thiopurine [14] and treat-to-target strategy [15], may play role on the changes long-term disease outcomes. The UC-related hospitalization and colectomy rates in our population were lower than those in the West [3]. We also demonstrated a reduction rate of UC-related hospitalization and colectomy over the past two decades. Between the 2000s and 2010s, the 5-year cumulative probabilities for UC-related hospitalization decreased from 30% to 21% and for colectomy decreased from 6% to 2%. A recent systemic review of Western studies showed that the 5-year cumulative probability of requiring UC-related hospitalization was 29% to 54%, and the colectomy rate at 5 years of disease was 10% [3].

There have been no population-based data about the change of UC incidence over time from Thailand, and other countries in Southeast Asia. A hospital-based registry study from Malaysia demonstrated the crude UC incidence in 1980s was 0.3 per 100,000 and increased to 0.9 per 100,000 in 2010-2018 [16]. Disease emergence in developing countries suggests that changing epidemiological trends are related to westernized lifestyle and industrialization. A population-based study from the AsiaPacific region revealed that a high-density population was more likely to develop UC [17]. Thus, in the 21st century, UC is becoming a burden disease across Asia [1]. Our results may help a newly industrialized country with a low incidence of UC with further investigations regarding environmental determinants of UC development, planning for a local health care strategy to modify the disease course of UC, and providing comprehensive information about disease prognosis to a patient for making a treatment decision.

A strength of this study is that all patients were meticulously longitudinally reviewed by 2 experts rather than relying on administrative data. All incident patients were followed from disease onset until the end of the study period. However, this study has several limitations. First limitation is a retrospective nature of the study; any data not recorded in the medical records would have been missed. Second, this study is a hospital-based study. Therefore, our patients would have more severe disease than these from a population-based study. We estimated the natural history of UC would be less aggressive in the national level. Third, changes in disease extent and endoscopic healing may not be accurate. Endoscopic evaluation was not performed routinely for all patients. In our practice, we generally perform endoscopic assessment in patient with flare-up disease. For patients with active disease, we usually perform endoscopic assessment every 6–12 months. Fourth, we did not classify disease activity according to disease activity indexes such as Mayo scores. Because disease course of UC is dynamic from disease in remission to severe disease over time, adjustment for the activity of disease would have been complicated. Fifth, we did not perform the analysis on time to initiation treatment of mesalamine and systemic corticosteroids. Certain therapies, most notably mesalamine was prescribed as an initial treatment for mild to moderate disease activity whereas systemic corticosteroid was prescribed as an initial treatment for severe disease activity. However, our study allows for an assessment of ever used of combination oral and topical of mesalamine and ever used of systemic corticosteroid in UC patients. Last, the ethnic diversity in Bangkok was less than in the Asia region. Therefore, these results would limit the generalization to the country with more diverse ethnicities.

In conclusion, the disease course of UC in Thailand was less aggressive in term of the rates of systemic corticosteroid use, biologic use, colectomy and UC-related hospitalization than in the West. Over the two decades, the rates of UC-related hospitalization and colectomy have been decreasing which were similar to the West.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contribution

Conceptualization: Aniwan S, Limsrivilai J. Methodology: Aniwan S, Limsrivilai J. Formal analysis: Aniwan S. Data acquisition: Aniwan S, Limsrivilai J, Pongprasobchai S, Pausawasdi N, Prueksapanich P, Kongtub N, Rerknimitr R. Writing - original draft: Aniwan S. Writing - review and editing: Aniwan S, Limsrivilai J. Approval of final manuscript: all authors.

Fig. 1.

Cumulative probability of thiopurine use (A) and endoscopic mucosal healing (B) stratified by the calendar year of diagnosis. UC, ulcerative colitis.

Fig. 2.

Cumulative probability of requiring ulcerative colitis (UC)-related hospitalization (A) and colectomy (B) stratified by the calendar year of diagnosis.

Table 1.

Characteristics of 291 Patients with UC Diagnosed between 2000–2009 and 2010–2018

Characteristics	UC cohort (n=291)		P-value
Characteristics	2000–2009 (n=119)	2010–2018 (n=172)	P-value
Female sex	63 (53)	88 (51)	0.77
Median age at diagnosis (yr)	42 (32–52)	42 (32–58)	0.16
Median duration of symptom onset (yr)	0.4 (0.2–1.1)	0.4 (0.1–1.0)	0.99
BMI at diagnosis (kg/m²)	22.1 ± 3.7	21.9 ± 3.4	0.68
Smoking status at diagnosis			0.90
Current smoker	1 (1)	2 (1)
Ex-smoker	12 (10)	15 (9)
Non-smoker	106 (89)	155 (90)
Appendectomy	6 (5)	6 (4)	0.51
First degree relative with IBD diagnosis	0	0	NA
UC location at diagnosis			0.75
Proctitis	23 (20)	39 (23)
Left-sided colitis	42 (35)	61 (35)
Extensive colitis	54 (45)	72 (42)
Extraintestinal manifestation	13 (10)	16 (9)	0.65
Ever used UC medications
Oral mesalamine	85 (71)	132 (77)	0.31
Combined topical and oral mesalamine	34 (29)	85 (49)	< 0.01
Systemic corticosteroids	75 (63)	110 (64)	0.87
Thiopurine	65 (55)	90 (52)	0.70
Biologic agent	3 (3)	1 (1)	0.31
UC disease severity^a	81 (68)	112 (65)	0.60

Values are presented as number (%), median (interquartile range), or mean±standard deviation.

^a UC disease severity defined as requiring systemic corticosteroid, biologic agent, or colectomy.

UC, ulcerative colitis; BMI, body mass index; IBD, inflammatory bowel disease; NA, not available.

Table 2.

Univariate and Multivariate Analysis for Risk of Achieving Endoscopic Healing in 252 Patients with UC Diagnosis between 2000 and 2018

Endoscopic healing	Univariate analysis		Multivariate analysis
Endoscopic healing	HR (95% CI)	P-value	HR (95% CI)	P-value
Male sex	0.65 (0.46–0.94)	0.02	0.71 (0.50–0.97)	0.07
Age at diagnosis (< 40 yr)	0.71 (0.49–1.01)	0.06	0.69 (0.48–1.00)	0.05
BMI (per 1 unit increase)	1.03 (0.98–1.08)	0.26	-	-
Ever/current smoker	1.07 (0.61–1.86)	0.82	-	-
Extensive colitis	0.76 (0.53–1.09)	0.10	0.82 (0.57–1.17)	0.28
Extraintestinal manifestation	0.73 (0.40–1.33)	0.30	-	-
Calendar period of diagnosis in 2000–2009	0.55 (0.38–0.79)	< 0.01	0.54 (0.37–0.79)	< 0.01

UC, ulcerative colitis; HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Table 3.

Univariate and Multivariate Analysis for Risk of UC-Related Hospitalization and Colectomy in 291 Patients with UC Diagnosis between 2000 and 2018

Factor	Univariate analysis		Multivariate analysis
Factor	HR (95% CI)	P-value	HR (95% CI)	P-value
UC-related hospitalization
Male sex	1.41 (0.86–2.33)	0.18	-	-
Age at diagnosis (< 40 yr)	1.14 (0.69 –1.87)	0.61	-	-
BMI (per 1 unit increase)	1.00 (0.93–1.08)	0.93	-	-
Ever/current smoker	0.57 (0.21–1.56)	0.27	-	-
Extensive colitis	2.83 (1.66–4.82)	< 0.01	2.82 (1.66–4.82)	< 0.01
Extraintestinal manifestation	1.79 (0.91–3.52)	0.09	1.63 (0.83–3.21)	0.16
Calendar period of diagnosis in 2000-2009	1.64 (1.00–2.71)	0.05	1.70 (1.03–2.81)	0.04
Colectomy
Male sex	1.23 (0.45–3.30)	0.69	-	-
Age at diagnosis (< 40 yr)	0.46 (0.16–1.35)	0.16	-	-
BMI (per 1 unit increase)	1.00 (0.87–1.15)	1.00	-	-
Ever/current smoker	0.71 (0.09–5.44)	0.74	-	-
Extensive colitis	2.14 (0.77–6.00)	0.10	1.96 (0.69–5.51)	0.20
Extraintestinal manifestation	0.50 (0.07–3.80)	0.50	-	-
Calendar period of diagnosis in 2000-2009	2.97 (0.98–8.96)	0.05	2.81 (0.92–8.61)	0.07

UC, ulcerative colitis; HR, hazard ratio; CI, confidence interval; BMI, body mass index.

REFERENCES

1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.Article
2. Aniwan S, Harmsen WS, Tremaine WJ, Kane SV, Loftus EV Jr. Overall and cause-specific mortality of inflammatory bowel disease in Olmsted county, Minnesota, from 1970 through 2016. Mayo Clin Proc 2018;93:1415–1422.Article PubMed PMC
3. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol 2018;16:343–356.Article PubMed
4. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asiapacific Crohn’s and colitis epidemiology study. Gastroenterology 2013;145:158–165.Article PubMed
5. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336–343.Article PubMed PMC
6. Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries. Gastroenterology 2018;155:1079–1089.Article PubMed
7. Eriksson C, Cao Y, Rundquist S, et al. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. Aliment Pharmacol Ther 2017;46:748–757.Article PubMed
8. Ng SC, Zeng Z, Niewiadomski O, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology 2016;150:86–95.Article PubMed
9. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014;109:705–714.Article PubMed PDF
10. Jeuring SF, Bours PH, Zeegers MP, et al. Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis 2015;9:837–845.Article PubMed PDF
11. Vegh Z, Burisch J, Pedersen N, et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J Crohns Colitis 2014;8:1506–1515.Article PubMed PDF
12. Targownik LE, Tennakoon A, Leung S, Lix LM, Singh H, Bernstein CN. Temporal trends in initiation of therapy with tumor necrosis factor antagonists for patients with inflammatory bowel disease: a population-based analysis. Clin Gastroenterol Hepatol 2017;15:1061–1070.Article PubMed
13. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2012;107:167–176.Article PubMed PDF
14. Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut 2019;68:623–632.Article PubMed
15. Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol 2019;114:874–883.Article PubMed PMC
16. Mokhtar NM, Nawawi KNM, Verasingam J, et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Public Health 2019;19:550.Article PubMed PMC PDF
17. Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol 2019;114:107–115.Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis
Ahmed Mohsin Huran Al-Jawadri, Zahra Karami, Ismaeil Haririan, Mohammad Akrami, Mahdi Gholami
Journal of Drug Targeting.2025; : 1. CrossRef
Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Digestive Diseases and Sciences.2023; 68(6): 2165. CrossRef
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
Digestive Diseases and Sciences.2022; 67(7): 2866. CrossRef
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
Gut and Liver.2022; 16(1): 138. CrossRef
Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
Journal of Personalized Medicine.2022; 12(3): 507. CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
United European Gastroenterology Journal.2022; 10(10): 1063. CrossRef
Current status of IBD and surgery of Crohn's disease in Thailand
Woramin Riansuwan, Julajak Limsrivilai
Annals of Gastroenterological Surgery.2021; 5(5): 597. CrossRef
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
Gut and Liver.2021; 15(6): 942. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018

Intest Res. 2021;19(2):186-193. Published online August 18, 2020

DOI: https://doi.org/10.5217/ir.2020.00028

XML Download

Figure

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018

Fig. 1. Cumulative probability of thiopurine use (A) and endoscopic mucosal healing (B) stratified by the calendar year of diagnosis. UC, ulcerative colitis.

Fig. 2. Cumulative probability of requiring ulcerative colitis (UC)-related hospitalization (A) and colectomy (B) stratified by the calendar year of diagnosis.

Fig. 1.

Fig. 2.

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018

Characteristics	UC cohort (n=291)		P-value
Characteristics	2000–2009 (n=119)	2010–2018 (n=172)	P-value
Female sex	63 (53)	88 (51)	0.77
Median age at diagnosis (yr)	42 (32–52)	42 (32–58)	0.16
Median duration of symptom onset (yr)	0.4 (0.2–1.1)	0.4 (0.1–1.0)	0.99
BMI at diagnosis (kg/m²)	22.1 ± 3.7	21.9 ± 3.4	0.68
Smoking status at diagnosis			0.90
Current smoker	1 (1)	2 (1)
Ex-smoker	12 (10)	15 (9)
Non-smoker	106 (89)	155 (90)
Appendectomy	6 (5)	6 (4)	0.51
First degree relative with IBD diagnosis	0	0	NA
UC location at diagnosis			0.75
Proctitis	23 (20)	39 (23)
Left-sided colitis	42 (35)	61 (35)
Extensive colitis	54 (45)	72 (42)
Extraintestinal manifestation	13 (10)	16 (9)	0.65
Ever used UC medications
Oral mesalamine	85 (71)	132 (77)	0.31
Combined topical and oral mesalamine	34 (29)	85 (49)	< 0.01
Systemic corticosteroids	75 (63)	110 (64)	0.87
Thiopurine	65 (55)	90 (52)	0.70
Biologic agent	3 (3)	1 (1)	0.31
UC disease severity^a	81 (68)	112 (65)	0.60

Endoscopic healing	Univariate analysis		Multivariate analysis
Endoscopic healing	HR (95% CI)	P-value	HR (95% CI)	P-value
Male sex	0.65 (0.46–0.94)	0.02	0.71 (0.50–0.97)	0.07
Age at diagnosis (< 40 yr)	0.71 (0.49–1.01)	0.06	0.69 (0.48–1.00)	0.05
BMI (per 1 unit increase)	1.03 (0.98–1.08)	0.26	-	-
Ever/current smoker	1.07 (0.61–1.86)	0.82	-	-
Extensive colitis	0.76 (0.53–1.09)	0.10	0.82 (0.57–1.17)	0.28
Extraintestinal manifestation	0.73 (0.40–1.33)	0.30	-	-
Calendar period of diagnosis in 2000–2009	0.55 (0.38–0.79)	< 0.01	0.54 (0.37–0.79)	< 0.01

Factor	Univariate analysis		Multivariate analysis
Factor	HR (95% CI)	P-value	HR (95% CI)	P-value
UC-related hospitalization
Male sex	1.41 (0.86–2.33)	0.18	-	-
Age at diagnosis (< 40 yr)	1.14 (0.69 –1.87)	0.61	-	-
BMI (per 1 unit increase)	1.00 (0.93–1.08)	0.93	-	-
Ever/current smoker	0.57 (0.21–1.56)	0.27	-	-
Extensive colitis	2.83 (1.66–4.82)	< 0.01	2.82 (1.66–4.82)	< 0.01
Extraintestinal manifestation	1.79 (0.91–3.52)	0.09	1.63 (0.83–3.21)	0.16
Calendar period of diagnosis in 2000-2009	1.64 (1.00–2.71)	0.05	1.70 (1.03–2.81)	0.04
Colectomy
Male sex	1.23 (0.45–3.30)	0.69	-	-
Age at diagnosis (< 40 yr)	0.46 (0.16–1.35)	0.16	-	-
BMI (per 1 unit increase)	1.00 (0.87–1.15)	1.00	-	-
Ever/current smoker	0.71 (0.09–5.44)	0.74	-	-
Extensive colitis	2.14 (0.77–6.00)	0.10	1.96 (0.69–5.51)	0.20
Extraintestinal manifestation	0.50 (0.07–3.80)	0.50	-	-
Calendar period of diagnosis in 2000-2009	2.97 (0.98–8.96)	0.05	2.81 (0.92–8.61)	0.07

Table 1. Characteristics of 291 Patients with UC Diagnosed between 2000–2009 and 2010–2018

Values are presented as number (%), median (interquartile range), or mean±standard deviation.

UC disease severity defined as requiring systemic corticosteroid, biologic agent, or colectomy.

UC, ulcerative colitis; BMI, body mass index; IBD, inflammatory bowel disease; NA, not available.

Table 2. Univariate and Multivariate Analysis for Risk of Achieving Endoscopic Healing in 252 Patients with UC Diagnosis between 2000 and 2018

UC, ulcerative colitis; HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Table 3. Univariate and Multivariate Analysis for Risk of UC-Related Hospitalization and Colectomy in 291 Patients with UC Diagnosis between 2000 and 2018

UC, ulcerative colitis; HR, hazard ratio; CI, confidence interval; BMI, body mass index.